Source: Virtual Congress 2021 – Acute respiratory distress syndrome phenotypes: implications for diagnosis and treatment



Rating:

Share or cite this content

Citations should be made in the following way:
C. Summers (Cambridge (Cambridgeshire), United Kingdom). Personalised medicine through biological subphenotyping of ARDS. Virtual Congress 2021 – Acute respiratory distress syndrome phenotypes: implications for diagnosis and treatment

Member's Comments

No comment yet.

Related content which might interest you: Personalised medicine in exacerbations of COPD: the beginnings Source: Eur Respir J 2012; 40: 1318-1319 Year: 2012 Personalised medicine through ventilator settings: implications of lung morphology in ARDS Source: Virtual Congress 2021 – Acute respiratory distress syndrome phenotypes: implications for diagnosis and treatment Year: 2021 Biomarkers and personalised medicine for asthma Source: Eur Respir J, 53 (1) 1802094; 10.1183/13993003.02094-2018 Year: 2019 Personalised medicine in interstitial lung diseases Source: Eur Respir Rev, 27 (148) 170117; 10.1183/16000617.0117-2017 Year: 2018 Predictive and personalised medicine for asthma using genomics Source: Annual Congress 2012 - Genetics and genomics in asthma and COPD: prediction and personalised medicine Year: 2012 Personalised medicine through individual approaches to resolve lung injury Source: Virtual Congress 2021 – Acute respiratory distress syndrome phenotypes: implications for diagnosis and treatment Year: 2021 Personalised targeted medicine Source: Research Seminar 2015 - Personalising respiratory care in Europe Year: 2015 Personalised medicine in paediatric asthma, including from the patient's perspective Source: International Congress 2016 – PG8 Paediatric asthma Year: 2016 Personalised medicine in asthma: from curative to preventive medicine Source: Eur Respir Rev 2017; 26: 160010 Year: 2017 Biomarkers in respiratory medicine Source: International Congress 2014 – PG03 Respiratory medicine: diagnosis to treatment from a mentor and junior perspective Year: 2014 Personalised medicine in asthma: time for action Source: Eur Respir Rev, 26 (145) 170064; 10.1183/16000617.0064-2017 Year: 2017 Patient-centred medicine in ILDs: towards a holistic approach Source: Virtual Congress 2021 – Holistic care in interstitial lung disease: monitoring the patient’s pathway Year: 2021 The future of personalised medicine in COPD Source: International Congress 2016 – Endotyping: the means to personalised medicine in lung disease Year: 2016 Consensus-based recommendations in respiratory medicine Source: Eur Respir J, 56 (6) 2002889; 10.1183/13993003.02889-2020 Year: 2020 Leadership in clinical medicine from respiratory perspective Source: Annual Congress 2013 –Improving educational programmes for patients and multidisciplinary healthcare professionals Year: 2013 Asthma susceptibility: from pathophysiology to personalised medicine Source: International Congress 2015 – ME4 Asthma susceptibility Year: 2015 Personalised pulmonary rehabilitation in COPD Source: Eur Respir Rev, 27 (147) 170125; 10.1183/16000617.0125-2017 Year: 2018 Update of the European paediatric respiratory medicine syllabus Source: Breathe, 15 (3) 173; 10.1183/20734735.0188-2019 Year: 2019 Real-world research and its importance in respiratory medicine Source: Breathe 2015; 11:26-38 Year: 2015